These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31449314)

  • 1. Long-term Use of Topical Bimatoprost on Rhododendrol-induced Refractory Leukoderma: A Case Report.
    Fukaya S; Kamata M; Kasanuki T; Yokobori M; Takeoka S; Hayashi K; Tanaka T; Fukuyasu A; Ishikawa T; Ohnishi T; Iimuro S; Watanabe S; Tada Y
    Acta Derm Venereol; 2019 Nov; 99(12):1178-1179. PubMed ID: 31449314
    [No Abstract]   [Full Text] [Related]  

  • 2. Open-label pilot study to evaluate the effectiveness of topical bimatoprost on rhododendrol-induced refractory leukoderma.
    Fukaya S; Kamata M; Kasanuki T; Yokobori M; Takeoka S; Hayashi K; Tanaka T; Fukuyasu A; Ishikawa T; Ohnishi T; Iimuro S; Tada Y; Watanabe S
    J Dermatol; 2018 Nov; 45(11):1283-1288. PubMed ID: 30156328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and epidemiological analysis in 149 cases of rhododendrol-induced leukoderma.
    Yoshikawa M; Sumikawa Y; Hida T; Kamiya T; Kase K; Ishii-Osai Y; Kato J; Kan Y; Kamiya S; Sato Y; Yamashita T
    J Dermatol; 2017 May; 44(5):582-587. PubMed ID: 27882588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fractional Resurfacing and Topical Bimatoprost for the Treatment of Laser Induced Postinflammatory Hypopigmentation on the Lower Extremities.
    Regis A; MacGregor J; Chapas A
    Dermatol Surg; 2018 Jun; 44(6):883-886. PubMed ID: 28961640
    [No Abstract]   [Full Text] [Related]  

  • 5. Melanocyte-specific cytotoxic T lymphocytes in patients with rhododendrol-induced leukoderma.
    Fujiyama T; Ikeya S; Ito T; Tatsuno K; Aoshima M; Kasuya A; Sakabe J; Suzuki T; Tokura Y
    J Dermatol Sci; 2015 Mar; 77(3):190-2. PubMed ID: 25724360
    [No Abstract]   [Full Text] [Related]  

  • 6. Biochemical, cytological, and immunological mechanisms of rhododendrol-induced leukoderma.
    Tokura Y; Fujiyama T; Ikeya S; Tatsuno K; Aoshima M; Kasuya A; Ito T
    J Dermatol Sci; 2015 Mar; 77(3):146-9. PubMed ID: 25726326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of a topical vitamin D3 analog on repigmentation in mice with rhododendrol-induced leukoderma.
    Abe Y; Okamura K; Ito S; Hozumi Y; Suzuki T
    J Dermatol Sci; 2022 May; 106(2):127-129. PubMed ID: 35487790
    [No Abstract]   [Full Text] [Related]  

  • 8. Substantial evidence for the rhododendrol-induced generation of hydroxyl radicals that causes melanocyte cytotoxicity and induces chemical leukoderma.
    Gabe Y; Miyaji A; Kohno M; Hachiya A; Moriwaki S; Baba T
    J Dermatol Sci; 2018 Sep; 91(3):311-316. PubMed ID: 30005897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An immune pathological and ultrastructural skin analysis for rhododenol-induced leukoderma patients.
    Tanemura A; Yang L; Yang F; Nagata Y; Wataya-Kaneda M; Fukai K; Tsuruta D; Ohe R; Yamakawa M; Suzuki T; Katayama I
    J Dermatol Sci; 2015 Mar; 77(3):185-8. PubMed ID: 25676426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible involvement of CCR4+ CD8+ T cells and elevated plasma CCL22 and CCL17 in patients with rhododenol-induced leukoderma.
    Nishioka M; Tanemura A; Yang L; Tanaka A; Arase N; Katayama I
    J Dermatol Sci; 2015 Mar; 77(3):188-90. PubMed ID: 25766765
    [No Abstract]   [Full Text] [Related]  

  • 11. Glutathione maintenance is crucial for survival of melanocytes after exposure to rhododendrol.
    Kondo M; Kawabata K; Sato K; Yamaguchi S; Hachiya A; Takahashi Y; Inoue S
    Pigment Cell Melanoma Res; 2016 Sep; 29(5):541-9. PubMed ID: 27223685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disfiguring Leukoderma Caused by Banned Cosmetics: A Quiz.
    Atzori L; Zanniello R; Sarais G; Piras V; Pilloni L; Zucca M; Brundu MA; Rongioletti F
    Acta Derm Venereol; 2018 Oct; 98(9):914-915. PubMed ID: 29944166
    [No Abstract]   [Full Text] [Related]  

  • 13. Zebrafish as a new model for rhododendrol-induced leukoderma.
    Hayazaki M; Hatano O; Shimabayashi S; Akiyama T; Takemori H; Hamamoto A
    Pigment Cell Melanoma Res; 2021 Nov; 34(6):1029-1038. PubMed ID: 34310852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical analysis of rhododendrol-induced leukoderma in improved and aggravated cases.
    Yasuda M; Sekiguchi A; Kishi C; Toki S; Arase N; Takahashi A; Yang F; Tanemura A; Hayashi M; Abe Y; Hamada T; Suzuki T; Katayama I; Ishikawa O
    J Dermatol Sci; 2020 Aug; 99(2):140-143. PubMed ID: 32653297
    [No Abstract]   [Full Text] [Related]  

  • 15. Re-pigmentation of Hypopigmentation: Fractional Lasers vs Laser-Assisted Delivery of Bimatoprost vs Epidermal Melanocyte Harvesting System.
    Waibel JS; Rudnick A; Arheart KL; Nagrani N; Gonzalez A; Gianatasio C
    J Drugs Dermatol; 2019 Nov; 18(11):1090-1096. PubMed ID: 31738492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rhododendrol-induced leukoderma accompanied by allergic contact dermatitis caused by a non-rhododendrol skin-lightening agent, 5,5'-dipropylbiphenyl-2,2'-diol.
    Yagami A; Suzuki K; Sano A; Takahashi M; Kobayashi T; Morita Y; Ando A; Iwata Y; Matsunaga K
    J Dermatol; 2015 Jul; 42(7):739-40. PubMed ID: 25875673
    [No Abstract]   [Full Text] [Related]  

  • 17. 4-(4-hydroroxyphenyl)-2-butanol (rhododendrol) activates the autophagy-lysosome pathway in melanocytes: insights into the mechanisms of rhododendrol-induced leukoderma.
    Yang L; Yang F; Wataya-Kaneda M; Tanemura A; Tsuruta D; Katayama I
    J Dermatol Sci; 2015 Mar; 77(3):182-5. PubMed ID: 25680854
    [No Abstract]   [Full Text] [Related]  

  • 18. Retention of pigment stem cells in Rhododenol-induced leukoderma: Pathological investigation of 11 patients.
    Watanabe S; Yagami A; Iwata Y; Nagai A; Kuroda M; Sugiura K; Matsunaga K
    J Dermatol; 2017 Jul; 44(7):e148-e149. PubMed ID: 28516676
    [No Abstract]   [Full Text] [Related]  

  • 19. Guide for medical professionals (i.e., dermatologists) for the management of Rhododenol-induced leukoderma.
    Nishigori C; Aoyama Y; Ito A; Suzuki K; Suzuki T; Tanemura A; Ito M; Katayama I; Oiso N; Kagohashi Y; Sugiura S; Fukai K; Funasaka Y; Yamashita T; Matsunaga K
    J Dermatol; 2015 Feb; 42(2):113-28. PubMed ID: 25622988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depigmentation caused by application of the active brightening material, rhododendrol, is related to tyrosinase activity at a certain threshold.
    Kasamatsu S; Hachiya A; Nakamura S; Yasuda Y; Fujimori T; Takano K; Moriwaki S; Hase T; Suzuki T; Matsunaga K
    J Dermatol Sci; 2014 Oct; 76(1):16-24. PubMed ID: 25082450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.